E. Zhu

发表

Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)

F. Saad, E. Posadas, K. Chi, 2021, Cancer Chemotherapy and Pharmacology.

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.

B. Leyland-Jones, E. Vercammen, I. Bondarenko, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

D. Esseltine, B. Coiffier, P. Zinzani, 2012, Journal of Hematology & Oncology.

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

D. Niederwieser, R. Hoffman, A. Vannucchi, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B. Coiffier, M. Crump, J. Walewski, 2011 .

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

F. Saad, H. Scher, D. George, 2019, Annals of Oncology.

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

D. Niederwieser, R. Hoffman, A. Reiter, 2018, Blood.

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.

Eugene Zhu, Shalini Chaturvedi, H. Eom, 2015, Blood.

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data

A. Vannucchi, J. Mascarenhas, R. Komrokji, 2021, Annals of Hematology.

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

D. Esseltine, S. de Vos, B. Coiffier, 2011, The Lancet. Oncology.

Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.

F. Saad, H. Scher, D. George, 2020 .

[Increasing number and improved survival of patients with hepatocellular carcinoma from 1988 to 2007: data of a German university clinic].

D. Blondin, D. Häussinger, W. Knoefel, 2011, Zeitschrift fur Gastroenterologie.

PS1456 FAVORABLE OVERALL SURVIVAL OF IMETELSTAT-TREATED RELAPSED/REFRACTORY MYELOFIBROSIS PATIENTS COMPARED WITH CLOSELY MATCHED REAL WORLD DATA

A. Vannucchi, J. Mascarenhas, R. Komrokji, 2019, HemaSphere.